INIS
patients
100%
viruses
64%
hiv
61%
concentration
48%
hepatitis
42%
humans
42%
men
31%
drugs
30%
doses
26%
uptake
24%
populations
23%
netherlands
23%
coronaviruses
21%
diseases
21%
emergencies
21%
monitoring
21%
kidneys
21%
injuries
21%
membranes
21%
liver
21%
proteins
21%
peaks
21%
fibrosis
21%
people
21%
european union
21%
side effects
17%
recovery
11%
toxicity
10%
mitochondria
10%
hospitals
10%
Keyphrases
AIDS/HIV
42%
Intoxication
32%
Netherlands
23%
Inappropriate Treatment
21%
COVID-19
21%
Caregivers
21%
Ciprofloxacin
21%
Dolutegravir
21%
Intentional Overdose
21%
Peak Concentration
21%
Chronic Hepatitis C Virus Infection
21%
Older Men
21%
HIV-positive MSM
21%
Acute Kidney Injury
21%
Efavirenz
21%
Atripla
21%
Tenofovir Disoproxil Fumarate
21%
Abacavir
21%
Therapeutic Drug Monitoring
21%
Hydroxychloroquine
21%
Gentamicin
21%
Severe Bacterial Infection
21%
Liver Fibrosis
21%
Sepsis
21%
Critically Ill Patients
21%
Emergency Department
21%
Lamivudine
21%
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO)
21%
Triumeq
21%
Virus Hepatitis
21%
Pharmacology, Toxicology and Pharmaceutical Science
Toxic Injury
42%
HIV
42%
Hepatitis C
29%
Acute Hepatitis C
21%
Tenofovir Disoproxil
21%
Fibrosis
21%
Acute Kidney Failure
21%
Abacavir Plus Dolutegravir Plus Lamivudine
21%
Efavirenz
21%
Efavirenz Plus Emtricitabine Plus Tenofovir Disoproxil
21%
Gentamicin
21%
Liver Fibrosis
21%
Emtricitabine
21%
Therapeutic Drug Monitoring
21%
Sepsis
21%
Ciprofloxacin
21%
Bacterial Infection
21%
Hepatitis C Virus
21%
Virus Hepatitis
21%
Antiviral Drug
21%
Tenofovir
10%
Dolutegravir
6%
Lamivudine
6%
Abacavir
6%
Tablet
6%
Clinical Pharmacokinetics
5%
Hemodialysis
5%
Kidney Injury
5%
Pharmacokinetics
5%